Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Caleb K Stein, PhD, Nathalie Meurice, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Gregory J Ahmann, BS, Shulan Tian, MS, PhD, P. Leif Bergsagel, MD, Esteban Braggio, PhD, A. Keith Stewart, MB, ChB

Blood (2019) 134 (Supplement_1): 574.

https://doi.org/10.1182/blood-2019-130977

Published: 2019

Journal Articles

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Sandip Patel, MBBS, Tiffany George, MD, Tzu-Fei Wang, MD MPH, Sherry Mori Vogt, Pharm D, Edmund Folefac, MD, Ming Yin, MD

Blood (2019) 134 (Supplement_1): 3681.

https://doi.org/10.1182/blood-2019-130465

Published: 2019

Journal Articles

Identifying Combination Therapies Targeting Apoptosis Pathways in Pediatric Acute Myeloid Leukemia (CAuSAL Study)

Katrina Lappin, PhD BSc, Kyle B Matchett, PhD, Jaine Blayney, PhD, Ken I Mills, PhD FRCPath, BSc

Blood (2018) 132 (Supplement 1): 2731.

https://doi.org/10.1182/blood-2018-99-111234

Published: 2018

Journal Articles

In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy

Deepak Balaji balaji Thimiri Govinda Raj, PhD MSc, Andrea Cremaschi, PhD MSc, Sigrid Strand Skånland, PhD, Alexandra Gade, Fredrik H. Schjesvold, MD PhD, Geir Erland Tjønnfjord, MD DMsc, Ludvig A Munthe, Kjetil Tasken

Blood (2018) 132 (Supplement 1): 4676.

https://doi.org/10.1182/blood-2018-99-110357

Published: 2018

Journal Articles

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Ashwini Kumar, MRes, Dishaben Rameshbhai Malani, MSc, Bhagwan Yadav, PhD, Matti Kankainen, PhD, Swapnil Potdar, MSc, Mika Kontro, MD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD, Simon Anders, PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 1398.

https://doi.org/10.1182/blood.V130.Suppl_1.1398.1398

Published: 2017

Journal Articles

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Heikki Kuusanmäki, MSc, Maija Leppä, BSc, Mika Kontro, MD, Olli Dufva, BSc, Debashish Deb, MSc, Bhagwan Yadav, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 3821.

https://doi.org/10.1182/blood.V130.Suppl_1.3821.3821

Published: 2017

Journal Articles

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Disha Malani, MRes, Ashwini Kumar, MRes, Bhagwan Yadav, PhD, Mika Kontro, MD, Swapnil Potdar, MSc, Samuli Eldfors, MSc, Jani Saarela, Bjørn Tore Gjertsen, Riikka Karjalainen, Tero Aittokallio, Astrid Murumagi, Maija Wolf, PhD, Simon Anders, PhD, Krister Wennerberg, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2017) 130 (Supplement 1): 854.

https://doi.org/10.1182/blood.V130.Suppl_1.854.854

Published: 2017

Journal Articles

Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome

Wei Zhang, MS, Brett M Stevens, PhDBS, Elizabeth Elizabeth Budde, MD PhD, Stephen J. Forman, MD FACP, Craig T. Jordan, PhD, Enkhtsetseg Purev, MD PhD

Blood (2017) 130 (Supplement 1): 1917.

https://doi.org/10.1182/blood.V130.Suppl_1.1917.1917

Published: 2017

Journal Articles

A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies

Stephen E Spurgeon, MD, Rachel Cook, MD MS, Elie Traer, MD, Uma Borate, MD, Richard T. Maziarz, MD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Tara Macey, PhD, Kristen Werth, Brian Junio, Cristina E. Tognon, Motomi Mori, PhD, Marc Loriaux, MD PhD

Blood (2016) 128 (22): 4051.

https://doi.org/10.1182/blood.V128.22.4051.4051

Published: 2016

Journal Articles

Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML

Antonio Cavazos, MS, Helen Ma, MS, Juliana Maria Benito, PhD, Mark J. Levis, MD PhD, Naval Daver, MD, Amir Ashoorzadeh, PhD, Robert Anderson, MSc, PhD FNZIC, CChem, FRSC, Adam Patterson, Jeff Smaill, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 5210.

https://doi.org/10.1182/blood.V128.22.5210.5210

Published: 2016

Journal Articles

Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia

Sara Buhrlage, PhD, Ellen Weisberg, MD, Nathan Schauer, Jing Yang, PhD, Ilaria Lamberto, PhD, Laura Doherty, Atsushi Nonami, MDPhD, Amanda L. Christie, BS, David M. Weinstock, MD, Richard M. Stone, MD, Nathanael Gray, PhD, James D Griffin, MD

Blood (2016) 128 (22): 524.

https://doi.org/10.1182/blood.V128.22.524.524

Published: 2016

Journal Articles

Identification of Targeted Therapies for Rare Adult Mature T-Cell Leukemia Using Functional Ex Vivo Screening of Primary Patient Samples

Uma Borate, MD, Brianna A. Norris, Pierrette Lo, MS, Cristina E. Tognon, Brian Junio, Jeffrey W. Tyner, Brian J. Druker, MD

Blood (2016) 128 (22): 4720.

https://doi.org/10.1182/blood.V128.22.4720.4720

Published: 2016

Journal Articles

High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells

Sina Oppermann, Jarkko Ylanko, Yonghong Shi, Santosh Hariharan, Christopher C. Oakes, Patrick M. Brauer, Juan C. Zúñiga-Pflücker, Brian Leber, David E. Spaner, David W. Andrews

Blood (2016) 128 (7): 934–947.

https://doi.org/10.1182/blood-2015-12-687814

Published: 2016

Includes: Supplemental data

Journal Articles

Loss of the TLE4 AML Tumor Suppressor Gene Contributes to Leukemic Cell Proliferation, Differentiation Arrest, and Chemotherapy Resistance through a COX-Dependent Inflammatory Pathway

Thomas H Shin, David A Sweetser, MD,PhD

Blood (2015) 126 (23): 1241.

https://doi.org/10.1182/blood.V126.23.1241.1241

Published: 2015

Journal Articles

High Throughput Flow Screening Assays to Profile Cell-Mediated Killing

Kim Yen Luu, PhD, Thomas D Duensing, PhD

Blood (2015) 126 (23): 4629.

https://doi.org/10.1182/blood.V126.23.4629.4629

Published: 2015

Journal Articles

Big Data Approach to Identify Molecular Basis for Drug Sensitivity Phenotypes in Acute Myeloid Leukemia

Su-In Lee, PhD, Benjamin Logsdon, PhD, Akanksha Saxena, BS, Vivian Oehler, MD, Chris P. Miller, PhD, C. Anthony Blau, MD, Pamela S. Becker, MD PhD

Blood (2014) 124 (21): 265.

https://doi.org/10.1182/blood.V124.21.265.265

Published: 2014

Journal Articles

Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling

Sibasish Dolai, PhD, Keith CS Sia, BSc(Hons), Alissa K Robbins, BSc(Hons), Ling Zhong, PhD, Sue Heatley, PhD, Tiffaney Vincent, BS, Falko Hochgräfe, PhD, Raushan T. Kurmasheva, PhD, Deborah L White, PhD FFSc (RCPA), Peter J. Houghton, PhD, Malcolm A. Smith, MD PhD, David T. Teachey, MD, Roger J Daly, PhD, Mark J Raftery, PhD, Richard B. Lock, PhD

Blood (2014) 124 (21): 969.

https://doi.org/10.1182/blood.V124.21.969.969

Published: 2014

Journal Articles

Chemosensitizing Leukemia By Targeting the Leukemia Microenvironment with Vascular Disrupting Combretastatins

Raphael C Bosse, BS, Briana Wasserstrom, Elizabeth Wise, BS, Amy Meacham, MS, Christopher R. Cogle, MD

Blood (2014) 124 (21): 2315.

https://doi.org/10.1182/blood.V124.21.2315.2315

Published: 2014

Journal Articles

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Victor M. Rivera, PhD, Justin R. Pritchard, PhD, Francois Gonzalvez, PhD, Theresa Baker, Joseph M. Gozgit, PhD, Graeme Hodgson, PhD

Blood (2014) 124 (21): 1783.

https://doi.org/10.1182/blood.V124.21.1783.1783

Published: 2014

Journal Articles

Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse

Naga Poojitha Ojamies, MSc, Mika Kontro, MD, Maija Wolf, PhD, Henrik Edgren, PhD, Pekka Ellonen, MSc, Sonja Lagström, MSc, Tiina Hannunen, MSc, Tea Pemovska, MSc, Henrikki Almusa, MSc, Maija Lepistö, MSc, Caroline A Heckman, PhD, Krister Wennerberg, PhD, Kimmo Porkka, MD PhD, Olli Kallioniemi, MD PhD

Blood (2014) 124 (21): 1022.

https://doi.org/10.1182/blood.V124.21.1022.1022

Published: 2014

NARROW

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Identifying Combination Therapies Targeting Apoptosis Pathways in Pediatric Acute Myeloid Leukemia (CAuSAL Study)

In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy

Gene-Drug Interactions in AML Patients Identified By RNA Sequencing and Comprehensive Ex Vivo Drug Sensitivity and Resistance Testing

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles

Anti-CD123 CAR T-Cell Therapy for the Treatment of Myelodysplastic Syndrome

A Phase II Pilot Study of Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using an in Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies

Pre-Clinical Activity of Novel Hypoxia-Activated FLT3 Inhibitors in FLT3-Mutated AML

Inhibition of USP10 Induces Degradation of Oncogenic FLT3: A Novel Approach to Therapy of Leukemia

Identification of Targeted Therapies for Rare Adult Mature T-Cell Leukemia Using Functional Ex Vivo Screening of Primary Patient Samples

High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells

Loss of the TLE4 AML Tumor Suppressor Gene Contributes to Leukemic Cell Proliferation, Differentiation Arrest, and Chemotherapy Resistance through a COX-Dependent Inflammatory Pathway

High Throughput Flow Screening Assays to Profile Cell-Mediated Killing

Big Data Approach to Identify Molecular Basis for Drug Sensitivity Phenotypes in Acute Myeloid Leukemia

Targeted Cancer Therapy in High-Risk Pediatric Leukemia Using Global Phosphotyrosine Profiling

Chemosensitizing Leukemia By Targeting the Leukemia Microenvironment with Vascular Disrupting Combretastatins

Comparative TKI Profiling Analyses to Explore Potential Mechanisms of Ponatinib-Associated Arterial Thrombotic Events

Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only